Skip to main content

Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.

Publication ,  Journal Article
Davis, K; Wood, S; Dill, E; Fesko, Y; Bitting, RL; Harrison, MR; Armstrong, AJ; Moul, JW; George, DJ
Published in: Clin J Oncol Nurs
June 2015

BACKGROUND: Sipuleucel-T, an autologous cellular immunotherapy, is approved for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first personalized treatment for prostate cancer to be manufactured using the immune system of each individual patient. Patient preparation and compliance are critical because patients undergo serial leukapheresis and reinfusion procedures within a relatively short time period, which may result in transient reactions. OBJECTIVES: The study aims to identify patients best suited for sipuleucel-T treatment, provide an overview of treatment, and encourage infusion sites to consider a primary contact model for the efficient coordination of care. METHODS: Treatment experiences were evaluated from 124 patients with mCRPC who received sipuleucel-T from January 2010 to August 2013 according to current best practices. Feedback was collected from reflective interdisciplinary discussion within the sipuleucel-T delivery team (nurses, advanced practice providers, urologists, and medical oncologists). FINDINGS: Early patient identification and education on treatment rationale, delivery, and expectations help ensure a successful sipuleucel-T treatment experience. A multidisciplinary coordinated-care process can facilitate proficient sipuleucel-T delivery, and the selection of a primary contact for care coordination offers benefits, such as clear and efficient education.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin J Oncol Nurs

DOI

EISSN

1538-067X

Publication Date

June 2015

Volume

19

Issue

3

Start / End Page

297 / 303

Location

United States

Related Subject Headings

  • Tissue Extracts
  • Prostatic Neoplasms, Castration-Resistant
  • Patient Selection
  • Patient Education as Topic
  • North Carolina
  • Male
  • Leukapheresis
  • Immunotherapy
  • Humans
  • Continuity of Patient Care
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Davis, K., Wood, S., Dill, E., Fesko, Y., Bitting, R. L., Harrison, M. R., … George, D. J. (2015). Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution. Clin J Oncol Nurs, 19(3), 297–303. https://doi.org/10.1188/15.CJON.297-303
Davis, Kristen, Sarah Wood, Emily Dill, Yuri Fesko, Rhonda L. Bitting, Michael R. Harrison, Andrew J. Armstrong, Judd W. Moul, and Daniel J. George. “Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.Clin J Oncol Nurs 19, no. 3 (June 2015): 297–303. https://doi.org/10.1188/15.CJON.297-303.
Davis K, Wood S, Dill E, Fesko Y, Bitting RL, Harrison MR, et al. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution. Clin J Oncol Nurs. 2015 Jun;19(3):297–303.
Davis, Kristen, et al. “Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.Clin J Oncol Nurs, vol. 19, no. 3, June 2015, pp. 297–303. Pubmed, doi:10.1188/15.CJON.297-303.
Davis K, Wood S, Dill E, Fesko Y, Bitting RL, Harrison MR, Armstrong AJ, Moul JW, George DJ. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution. Clin J Oncol Nurs. 2015 Jun;19(3):297–303.

Published In

Clin J Oncol Nurs

DOI

EISSN

1538-067X

Publication Date

June 2015

Volume

19

Issue

3

Start / End Page

297 / 303

Location

United States

Related Subject Headings

  • Tissue Extracts
  • Prostatic Neoplasms, Castration-Resistant
  • Patient Selection
  • Patient Education as Topic
  • North Carolina
  • Male
  • Leukapheresis
  • Immunotherapy
  • Humans
  • Continuity of Patient Care